Treating Word Finding Difficulties in Traumatic Brain Injury With HD-tDCS
Launched by THE UNIVERSITY OF TEXAS AT DALLAS · Feb 17, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new way to help people who have had a traumatic brain injury (TBI) and struggle with finding the right words when speaking. The study is testing a method called transcranial Direct Current Stimulation (tDCS), which involves using a low level of electric stimulation on a specific part of the brain that is believed to help with memory. Researchers hope that this treatment will improve the ability to retrieve words in civilian participants who have experienced TBIs more than a year ago and have ongoing word-finding difficulties.
To participate in this study, individuals must be between 18 and 85 years old, have a history of mild to moderate traumatic brain injury confirmed by certain tests, and should not be military personnel or veterans. They also need to be fluent in English. Participants will undergo various assessments to measure their verbal abilities and overall cognitive skills before, during, and after the treatment. It’s important to know that some individuals, like those with specific medical conditions or devices, may not qualify for the study. If you or someone you know fits the criteria and is interested, this trial could provide valuable insights into improving communication after a brain injury.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between the ages of 18-85
- • Traumatic brain injury more than a year prior to study participation
- • Word finding difficulty since the brain injury
- • Fluent in speaking and reading English.
- Exclusion Criteria:
- • Implanted/electronic device, such as a pacemaker, metallic cranial or intracranial implant (e.g., ventriculoperitoneal shunt), or a neurostimulator (e.g., vagus nerve stimulator, spinal stimulator, deep brain stimulator, etc.).
- • Skull defects
- • History of a psychological or neurological disorder, including, dementia of any type, epilepsy or other seizure disorders, post-traumatic stress disorder, brain tumor, present drug abuse, stroke, blood vessel abnormalities in the brain, Parkinson's disease, Huntington's disease, or multiple sclerosis.
- • Inability to give informed consent
- • Military personnel or Veteran
- • Currently pregnant
- • Not fluent English speaker
About The University Of Texas At Dallas
The University of Texas at Dallas (UT Dallas) is a leading research institution dedicated to advancing knowledge and innovation across various disciplines, including health sciences and clinical research. As a clinical trial sponsor, UT Dallas leverages its robust academic infrastructure and interdisciplinary expertise to conduct rigorous studies aimed at improving patient outcomes and enhancing medical practices. The university fosters collaboration among researchers, clinicians, and industry partners, ensuring that its clinical trials adhere to the highest ethical standards and scientific integrity. Through its commitment to research excellence, UT Dallas aims to contribute significantly to the advancement of healthcare solutions and the understanding of complex medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Richardson, Texas, United States
Patients applied
Trial Officials
John Hart, MD
Principal Investigator
The University of Texas at Dallas
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported